H

ello, everyone, and how are you today? We are just fine, thank you, despite daunting weather that altered travel plans. Nonetheless, we managed to arrive at the JP Morgan health care fest, albeit not as soon as we hoped, and plan to scurry about meeting interesting people. As we indicated previously, this will call for sporadic posting. Nonetheless, we have assembled the usual menu of tidbits. We will now search for a cup of stimulation. Have a grand day and do keep in touch …

Johnson & Johnson is set to issue a report next month outlining how much it has raised US prices for its prescription drugs, the Wall Street Journal writes. The report will provide the average increase in list prices, as well as average prices after the discounts given by the health care giant. But J&J is not pledging to hold price hikes to single-digit increases, because the company maintains it already does so.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy